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Abstract
Purpose As data on this topic are sparse and contradictory, we aimed to ascertain the opinions of the members of the German 
Society of Gynecologic Endoscopy (AGE) regarding the use of robotic surgery in the treatment of ovarian malignancies.
Methods In 2015, an anonymous questionnaire was sent to AGE members to assess their views on the treatment of ovarian 
malignancies by robotic surgery according to T stage and the current treatment practices in their facilities.
Results Of the 228 respondents, 132 (58%) were fellows or attending physicians and 156 (68%) worked at university hos-
pitals or tertiary referral centers. Most [n = 218 (96%)] respondents reported treating < 10% of their patients using robotic 
surgery. Respondents felt that T1 and borderline ovarian tumors, but not T2 (51%) or T3/4 (76%) tumors, should and could 
be treated by robot surgery. 162 (71%) respondents considered the currently available data on this subject to be insufficient, 
and 42% indicated their willingness to participate in clinical studies on the applicability of robotic surgery to the treatment 
of T1/2 ovarian tumors.
Conclusion The majority of AGE members surveyed considered robotic surgery to be an option for the treatment of T1 
ovarian malignancies and borderline ovarian tumors. However, prospective randomized studies are needed to determine the 
relevance of robotic surgery in this context.
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Introduction
With approximately 7250 newly diagnosed cases per year, 
ovarian cancer is among the most frequently occurring 
cancers among women in Germany and the second leading 
cause of death from gynecological malignancies worldwide 
[1, 2]. Despite the optimization of chemotherapeutic regi-
mens and the development of new therapies, surgery (using 
optimal procedures) remains the core element of ovarian 
cancer treatment. Survival rates depend directly on the 
extent of debulking, notably on the achievement of complete 
cytoreduction (R0 resection), and on the amount of tumor 
remaining in the abdomen postoperatively [3, 4].
Laparotomy has been the gold standard for the surgical 
treatment of gynecological malignancies. With constant pro-
gress in laparoscopy and robotic surgery in past decades and 
the widespread use of minimally invasive surgery (MIS) for 
the treatment of benign gynecological diseases, the focus 
has shifted gradually to the use of robotic surgery for the 
treatment of gynecological malignancies [5]. The benefits 
of MIS include reduced postoperative pain intensity, wound 
infection rates, length of hospitalization, and procedure-
associated morbidity, as well as the possibility of immediate 
adjuvant therapy initiation. These advantages have led to the 
gradual implementation of laparoscopy and robotic surgery 
as alternatives to open surgery for the treatment of certain 
gynecologic malignancies [6]. Major concerns about MIS 
use in the gynecological context, however, are related to the 
ability to achieve sufficient oncological safety; they include 
the risks of intraoperative tumor rupture, port site metas-
tasis, and peritoneal dissemination of tumor cells, as well 
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as the questionable efficacy of surgical staging, which have 
prevented an implementation of laparoscopy and robotic sur-
gery for the treatment of ovarian cancer [7–9].
The German S3 guidelines for diagnosis, treatment, and 
surveillance of ovarian malignancies recommend the use of 
MIS only in clinical trials, as few data regarding the onco-
logical safety of these procedures are available and poten-
tial risks are not sufficiently recognized [10]. Internation-
ally, some institutions have made efforts to implement MIS 
for the treatment of early-stage ovarian cancer, staging of 
advanced disease, and assessment of the neoadjuvant treat-
ment response, and reported a comparable outcome of MIS 
in terms of feasibility and surgical parameters as against 
open surgery [11–13]. The role of MIS in the treatment of 
ovarian malignancies, however, remains controversial. This 
survey was conducted to assess the opinions of members 
of the German Society of Gynecologic Endoscopy (AGE) 
regarding the use of robotic surgery for the treatment of 
ovarian neoplasias and borderline tumors according to T 
stage, and to obtain information about current treatment 
practices in these members’ institutions.
Methods
The present survey was the second part of a two-part study 
of the use of MIS in the treatment of ovarian neoplasia. The 
first survey examined the use of laparoscopy in the treatment 
of ovarian malignancies, and has been reported on elsewhere 
[14].
Before starting the study, AGE created a task force for 
questionnaire design, survey implementation, and data 
analysis. The study design was approved by the executive 
board of AGE [14]. According to the local ethics committee 
regulations (Saarland institutional review board) no ethical 
approval was needed for this survey. Informed consent for 
publication was obtained from all survey participants.
From February to October 2015, an anonymous online 
survey was sent to AGE members via email, and posted on 
the homepage of the AGE website. Two email reminders 
were sent during this period. The online survey was accessed 
via the Google Drive online survey system (Google Ireland 
Limited, Dublin, Ireland). After the data collection period, 
a research associate at the Department of Gynecology and 
Obstetrics, Saarland University Hospital, Homburg, entered 
the data without respondent-identifying information into an 
Excel (version 2010; Microsoft Corporation, Redmond, WA, 
USA) database.
The first part of the questionnaire solicited demographic 
and workplace information, such as respondents’ age, sex, 
and education level, as well as the hospital level and annual 
ovarian cancer surgery volume and respondents’ possible 
concerns regarding the oncological safety and precision of 
MIS for ovarian cancer in general. Those results have been 
published within the first manuscript on laparoscopic treat-
ment of ovarian malignancies [14]. The second part solicited 
respondents’ opinions about the use of robotic surgery in the 
treatment of ovarian malignancies and borderline ovarian 
tumors, as well as information on current ovarian neopla-
sia treatment practices in their facilities. Respondents were 
asked about their opinions about the use of robotic surgery 
for ovarian neoplasia according to the T stage following the 
TNM classification for malignant tumors [15]. The next part 
of the survey solicited respondents’ opinions about currently 
available data on the use of robotic surgery in the treatment 
of ovarian neoplasia, and inquired about their willingness to 
participate in clinical trials on this topic. For the calculation 
of descriptive statistics, the data were transferred to SPSS 
(version 19; SPSS Inc., Chicago, IL, USA). Categorical data 
are reported as frequencies with percentages.
Results
In total, 235 physicians who were AGE members (18% of 
those contacted) took part in the online survey. Seven incom-
plete questionnaires were excluded, leaving 228 completed 
questionnaires that were included in the final analysis.
Respondent and practice characteristics
The sample comprised 128 (56%) male and 100 (44%) 
female gynecologists with a mean age of 36 (range, 26–62) 
years. 66 (29%) respondents were residents, 40 (18%) were 
fellows, 92 (40%) were attending physicians, and 30 (13%) 
were department heads. Almost half [n = 108 (47%)] of the 
respondents worked at university hospitals, 48 (21%) worked 
at clinics providing maximum or standard care, and 24 (11%) 
had private gynecological practices. One hundred twelve 
(49%) respondents indicated that they performed operations 
to treat ovarian malignancies and 172 (75%) indicated that 
they assisted with such interventions. 77 (34%) respond-
ents reported that < 20 such operations were performed per 
year in their facilities, 106 (46%) reported 20–50 interven-
tions per year, and 45 (20%) reported 50–100 interventions 
per year. Most [n = 218 (96%)] respondents indicated that 
robotic surgery was used in 0–10% of all ovarian cancer 
cases at their facilities (Table 1).
Current practice and perceived applicability 
of robotic surgery
42 (18%), 24 (10%), and 30 (13%) respondents reported 
that T1a, T1b, and T1c tumors, respectively, were treated 
with robotic surgery at their facilities; 164 (72%), 204 
(90%), and 198 (87%) respondents reported no such 
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practice for T1a–c tumors, respectively. 22 (10%) respond-
ents reported using robotic surgery to treat T1a tumors in 
clinical trials; no respondent reported such use for T1b 
or T1c tumors. 14 (6%) respondents reported T2 tumor 
treatment with robotic surgery, and 214 (94%) respondents 
reported no such practice. Similarly, 216 (95%) respond-
ents reported no use of robotic surgery to treat T3/4 ovar-
ian tumors, and 12 (5%) respondents reported using such 
treatment only in clinical trials (Table 2).
Reported concerns about the oncological safety of MIS in 
general were the inaccuracy of abdominal staging (30%) and 
the risks of ovarian tumor rupture (27%), intra-abdominal 
tumor cell spread (18%), and port-site metastasis (14%) [14]. 
24 (11%) respondents indicated that they saw no disadvan-
tage of the use of MIS relative to open surgery (Table 1) 
[14].
Approximately half of the respondents indicated that 
robotic surgery should or could be used to treat T1a [n = 136 
Table 1  Characteristics of 










 Head of department 30 (13%)
Hospital level
 University hospital 108 (47%)
 Tertiary hospital 48 (21%)
 Primary hosptial 48 (21%)
 Day hospital 0 (0%)
 Gynecological practice 24 (11%)
Do you perform surgery for treatment of ovarian malignancies yourself?
 Yes 112 (49%)
 No 116 (51%)
Do you assist in surgery for treatment of ovarian malignancies?
 Yes 172 (75%)
 No 56 (25%)
How many surgical procedures for primary ovarian malignancies are conducted at your insti-
tution per year?
 < 20 77 (34%)
 20–50 106 (46%)
 50–100 45 (20%)
 > 100 0 (0%)
How many percent of these patients are treated via robotic surgery?
 0% 197 (87%)
 < 10% 21 (9%)
 10–40% 5 (2%)
 > 50% 5 (2%)
Which concerns do you have regarding minimal invasive surgery treatment for ovarian malig-
nancies?
 Danger of intraabdominal tumor cell dissemination 40 (18%)
 Danger of port site metastasis 32 (14%)
 Danger of rupture of ovarian mass 64 (27%)
 Inaccuracy of peritoneal staging 68 (30%)
 No disadvantage compared to open surgery 24 (11%)
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(60%)], T1b [n = 108 (47%)], and T1c [n = 104 (46%)] tumors; 
52 (22%), 60 (26%), and 57 (25%) respondents indicated that 
robotic surgery should be used to treat these respective tumor 
types only in clinical trials, and 40 (18%), 60 (26%), and 67 
(29%) respondents, respectively, indicated that robotic surgery 
should not be used to treat these tumors. 56 (25%) respond-
ents indicated that T2 tumors should or could be treated with 
robotic surgery, 54 (24%) considered this application to be 
appropriate only in clinical trials, and 118 (51%) indicated 
that robotic surgery should not be used to treat T2 tumors. No 
respondent believed that robotic surgery should be used to treat 
T3/4 tumors, 21 (9%) respondents indicated that this technique 
could be used for these tumors, 35 (15%) accepted such use 
only in clinical trials, and 172 (76%) indicated that robotic 
surgery should not be used in such cases (Table 3).
Perspectives on available data and clinical trial 
participation
One hundred sixty-two (71%) respondents considered the 
currently available data on the use of robotic surgery to treat 
ovarian cancer to be insufficient, and 66 (29%) respondents 
could not provide any information. 98 (43%) and 50 (22%) 
of respondents respectively felt that further research on the 
use of robotic surgery to treat T1/2 and T3/4 ovarian can-
cer was needed. 95 (42%) respondents indicated that they 
were willing to participate in clinical trials investigating the 
robotic surgical treatment of T1/2 carcinomas; as optimal 
study designs, 128 (56%) respondents suggested a prospec-
tive randomized study, 68 (30%) suggested a meta-analysis, 
and 32 (14%) suggested a retrospective study. 50 (22%) 
respondents indicated that they would not participate in 
clinical trials on the use of robotic surgery in the treatment 
of T3/4 ovarian tumors, 53 (23%) respondents indicated that 
they would participate in such trials; and 50 (22%) could 
not provide any information; for research on this topic, 108 
(47%) respondents suggested a prospective randomized 
Table 2  Current practice at participant institution for robotic treat-
ment of ovarian cancer
N (%)
What is the current practice at your institution (depend-
ing on T stage of disease)?
 T1a tumors
  Are treated via robotic surgery 42 (18%)
  Are only treated as part of clinical trials via robotic 
surgery
22 (10%)
  Are not treated via robotic surgery 164 (72%)
 T1b tumors
  Are treated via robotic surgery 24 (10%)
  Are only treated as part of clinical trials via robotic 
surgery
0 (0%)
  Are not treated via robotic surgery 204 (90%)
 T1c tumors
  Are treated via robotic surgery 30 (13%)
  Are only treated as part of clinical trials via robotic 
surgery
0 (0%)
  Are not treated via robotic surgery 198 (87%)
 T2 tumors
  Are treated via robotic surgery 14 (6%)
  Are only treated as part of clinical trials via robotic 
surgery
0 (0%)
  Are not treated via robotic surgery 214 (94%)
 T3/4 tumors
  Are treated via robotic surgery 0 (0%)
  Are only treated as part of clinical trials via robotic 
surgery
12 (5%)
  Are not treated via robotic surgery 216 (95%)
Table 3  Participants opinion about robotic treatment of ovarian can-
cer
N (%)
What is your personal opinion on robotic treatment of 
ovarian cancer (depending on T stage of disease)?
 T1a tumors
  Should be treated via robotic surgery 40 (18%)
  Can be treated via robotic surgery 96 (42%)
  Should only be treated via robotic surgery in clinical 
trials
52 (22%)
  Should not be treated via robotic surgery 40 (18%)
 T1b tumors
  Should be treated via robotic surgery 32 (14%)
  Can be treated via robotic surgery 76 (33%)
  Should only be treated via robotic surgery in clinical 
trials
60 (26%)
  Should not be treated via robotic surgery 60 (26%)
 T1c tumors
  Should be treated via robotic surgery 32 (14%)
  Can be treated via robotic surgery 72 (32%)
  Should only be treated via robotic surgery in clinical 
trials
57 (25%)
  Should not be treated via robotic surgery 67 (29%)
 T2 tumors
  Should be treated via robotic surgery 22 (10%)
  Can be treated via robotic surgery 34 (15%)
  Should only be treated via robotic surgery in clinical 
trials
54 (24%)
  Should not be treated via robotic surgery 118 (51%)
 T3/4 tumors
  Should be treated via robotic surgery 0 (0%)
  Can be treated via robotic surgery 21 (9%)
  Should only be treated via robotic surgery clinical 
trials
35 (15%)
  Should not be treated via robotic surgery 172 (76%)
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study, 66 (29%) a meta-analysis, and 54 (24%) a retrospec-
tive study, respectively (Table 4).
Robotic surgery for borderline ovarian tumors
In total, 158 (69%) respondents stated that borderline ovar-
ian tumors would not be treated with robotic surgery in their 
practices, 45 (20%) respondents treated such tumors with 
robotic surgery at their facilities and 25 (11%) respondents 
reported the use of such treatment in clinical trials. 160 
(70%) respondents stated that borderline ovarian tumors 
should or could be treated with robotic surgery, and 34 
(15%) respondents each did and did not favor such treat-
ment within the framework of clinical studies. 126 (55%) 
respondents indicated that the treatment of borderline ovar-
ian tumors by robotic surgery required further evaluation, 49 
(22%) were opposed to new studies on the subject, and 53 
(23%) could not provide any information. Similar numbers 
of respondents reported that they would [n = 93 (41%)] and 
would not [n = 102 (45%)] participate in clinical trials on 
robotic surgical therapy for borderline ovarian tumors; as 
study designs, 34 (15%) respondents suggested a retrospec-
tive study, 54 (24%) a meta-analysis, and 140 (61%) a pro-
spective randomized controlled study, respectively (Table 5).
Discussion
The aim of the present study was to examine the opinion 
of the AGE members regarding the use of robotic surgery 
in the treatment of ovarian neoplasia and to survey the cur-
rent application of robotic surgery in their respective facili-
ties. This survey showed that the use of robotic surgery in 
the treatment of ovarian tumors was not prevalent in the 
facilities of responding AGE members; 28% of respondents 
indicated that T1a tumors were treated by robotic surgery, 
including in clinical studies, and the proportion declined 
with increasing tumor stage to 5% for T3/4 tumors in clinical 
trials alone. Thirty-one percent of respondents reported the 
use of robotic surgery to treat borderline ovarian tumors, of 
Table 4  Participants opinion about the currently available data on robotic treatment of ovarian cancer
N (%)
How would you assess current data on robotic treatment of ovarian cancer?
 Sufficient 0 (0%)
 Insufficient 162 (71%)
 I can’t tell 66 (29%)
Do you think robotic treatment for early stage ovarian cancer (T1/2) needs further evaluation?
 Yes 98 (43%)
 No 77 (34%)
 I can’t tell 53 (23%)
If yes, what kind of study would you suggest?
 Retrospective study 32 (14%)
 Meta-analysis 68 (30%)
 Prospective randomized controlled trial 128 (56%)
Would you take part in a clinical trial assessing robotic treatment of early stage (T1/2) ovarian cancer?
 Yes 95 (42%)
 No 89 (39%)
 I can’t tell 44 (19%)
Do you think robotic treatment of advanced ovarian cancer (T3/4) needs further evuluation?
 Yes 50 (22%)
 No 128 (56%)
 I can’t tell 50 (22%)
If yes, what kind of study would you suggest?
 Retrospective study 54 (24%)
 Meta-analysis 66 (29%)
 Prospective randomized controlled trial 108 (47%)
Would you take part in a clinical trial assessing robotic treatment of early stage (T3/4) ovarian cancer?
 Yes 53 (23%)
 No 124 (55%)
 I can’t tell 50 (22%)
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which 11% reported this application only in clinical trials. In 
contrast, AGE members favored the use of robotic surgery, 
especially for T1a–c tumors (60% for T1a and declining 
thereafter) and borderline tumors (70%).
These opinions coincide with findings from retrospective 
case–control studies conducted in Italy and China, which 
confirmed that the adequacy and reliability of robotic sur-
gery for the treatment of early-stage ovarian cancer, in terms 
of surgical outcome and oncological safety, were equiva-
lent to those of conventional laparotomy, although sample 
sizes were small (7–33 patients) [16–18]. Other groups have 
proposed the use of robotic surgery at least for the staging 
of early ovarian cancer in selected patient groups, and as 
a possible alternative to laparoscopy when performed by 
gynecologists with surgical experience [19, 20].
The literature contains contradictory information about 
differences in the outcomes of robotic surgery and conven-
tional laparoscopy. In a prospective randomized study of 
endometrial cancer treatment, Mäenpää et al. [21] showed 
that surgical outcomes were equivalent, although robot-
assisted surgery reduced the operating time and rate of con-
version to laparotomy relative to conventional laparoscopy. 
In contrast, El Khouly et al. [22] observed equivalent tech-
nical efficiency of the two techniques, but shorter operating 
times for conventional laparoscopy performed to remove 
adnexal findings the same technical efficiency.
Nezhat et al. [23] compared perioperative outcome and 
complication rates between laparotomy, laparoscopy and 
robotic surgery in the treatment of ovarian, tube and peri-
toneal cancer in their study. In contrast to the opinion of 
AGE members obtained in the present study, Nezhat et al., 
concluded in their retrospective study that laparoscopy and 
robotic surgery are not inferior to laparotomy in early and 
advanced stages with regard to perioperative outcome, and 
appear therefore as an acceptable alternative in the therapy 
of selected patients. In agreement with AGE members, other 
authors have expressed clear reservations about the use of 
robotic surgery for the treatment of T3/4 tumors [16–18].
Divergent perspectives on the safety of robotic surgery in 
the treatment of ovarian neoplasia, about which up to 30% 
of participants in the present study expressed concern, have 
been discussed in the literature. For example, some groups 
have argued that tumor capsule rupture is relevant for over-
all survival, whereas others have stated that intraoperative 
rupture does not shorten the progression-free survival time 
[24–26]. In a review, Minig et al. [20] expressed no concern 
about the use of robotic surgery in terms of inaccurate peri-
toneal staging, at least in the early stages of ovarian cancer, 
as long as the staging is performed by experienced surgeons 
in appropriate centers; they noted that further studies of the 
application of robotic surgery in advanced ovarian cancer 
staging are needed. With regard to intra-abdominal tumor 
Table 5  Participants opinion and current practice at their institution regarding robotic treatment of ovarian borderline tumors
N (%)
What is your personal opinion on robotic treatment of borderline tumors
 Should be treated via robotic surgery 70 (31%)
 Can be treated via robotic surgery 90 (39%)
 Should only be treated via robotic surgery in clinical trials 34 (15%)
 Should not be treated via robotic surgery 34 (15%)
What is the current practice at your institution (depending on T stage of disease)?
 Borderline tumors
  Are treated via robotic surgery 45 (20%)
  Are only treated as part of clinical trials via robotic surgery 25 (11%)
  Are not treated via robotic surgery 158 (69%)
Do you think robotic treamtent for ovarian borderline tumors needs further evaluation?
 Yes 126 (55%)
 No 49 (22%)
 I can’t tell 53 (23%)
If yes, what kind of study would you suggest?
 Retrospective study 34 (15%)
 Meta-analysis 54 (24%)
 Prospective randomized controlled trial 140 (61%)
Would you take part in a clinical trial assessing robotic treatment of ovarian borderline tumors?
 Yes 93 (41%)
 No 102 (45%)
 I can’t tell 33 (14%)
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cell carryover, animal experiments have shown the increased 
production of interleukins and growth factors in the pres-
ence of pneumoperitoneum, and in vitro experiments have 
shown increased ovarian carcinoma cell line growth rates 
after exposure to carbon dioxide [27, 28]. However, in vivo 
studies showed no increase in the frequency of recurrence 
after MIS compared with open surgery [29–31]. Seror et al. 
[32] found no metastasis in trocar site areas at a median 
of 504 days after the robotic surgical treatment of ovar-
ian, endometrial, and cervical carcinomas. Another group 
reported a low rate (1.41%) of port-site metastasis after the 
use of robotic surgery to treat gynecological malignancies, 
which coincided with the rate of metastasis in the puncture 
canal after traditional laparoscopy (1.96%) [9, 33]. These 
rates are also comparable to those of recurrence in the scar 
area after conventional laparotomy [34]. Whether the instru-
ments used in robotic surgery modify the risk of metastasis 
at trocar puncture sites has not been clarified sufficiently; 
further clinical studies are required [33].
The discrepancy between the currently limited use of 
robotic surgery in the treatment of ovarian malignancies 
(even T1a tumors) and AGE members’ opinions about the 
applicability of this technique can be attributed to the limita-
tions of robotic surgery in general, which have hampered the 
spread of this technique in Germany. The main limitations 
are the greater cost of equipment acquisition and mainte-
nance relative to that for conventional laparoscopy, and the 
associated lack of equipment available for treatment and 
research [35]. In addition, medical staff and surgeons require 
special training before they can routinely handle surgical 
robots [36]. According to the Deutsche Ärztezeitung, 135 
DaVinci® systems (Intuitive Surgical, Inc., Sunnyvale, CA, 
USA) were in clinical use in Germany in 2019, although 
(co-)use by gynecologists was not reported specifically [37]. 
Traditionally, urology is considered to be a pioneering dis-
cipline in the use of robotic surgery [38]. The members of 
AGE, a specialist society that concentrates on conventional 
laparoscopic operations and is composed mainly of surgeons 
versed in this technique, may lack robotic surgical expertise, 
contributing to their reluctance to use robotic surgery.
Advantages of robotic surgery over conventional laparot-
omy that are shared with those of conventional laparoscopy 
are reduced blood loss, operation time, postoperative pain, 
and hospitalization [39]. Advantages of robotic surgery over 
conventional laparoscopy are the more ergonomic working 
position and reduced fatigue rate for surgeons, free mobility 
of the instruments in seven degrees of freedom, and digital 
networking of surgical robots [40].
The current S3 guidelines for ovarian malignancies do 
not mention robotic surgery, and recommend laparoscopic 
staging only in the research context, due to the lack of suf-
ficient high-quality evidence [10]. This coincides with AGE 
members’ perspectives that further studies of robotic surgery 
in the gynecological context are needed, and their willing-
ness to participate in such studies. It also corresponds to the 
state of the literature. For example, Yim et al. [41] found in 
a review that the majority of studies of the use of robotic sur-
gery for the treatment of gynecological malignancies were 
retrospective or descriptive. Thus, prospective randomized 
studies of the application of this technique, at least to T1/2 
ovarian tumors, appear to be needed [42].
The United States’ National Comprehensive Cancer Net-
work guidelines mention only the use of conventional lapa-
roscopy by experienced surgeons for the primary treatment 
of T1a–c tumors; they recommend the use of a minimally 
invasive access route for intermittent tumor debulking, with 
possible intraoperative conversion to open surgery via an 
abdominal incision [43]. This less cautious approach to the 
use of MIS for ovarian cancer treatment, which is based on 
greater experience and more widespread practice, is also 
reflected in the current literature from the United States. Two 
retrospective studies showed that robotic surgery was equiv-
alent to conventional laparotomy. Feuer et al. [44] described 
equivalent tumor reduction (73% and 50%) and 1-year recur-
rence and survival rates (97% and 90%), regardless of tumor 
stage. Magrina et al. [45] observed no difference in overall 
survival after conventional laparoscopy (75%), robotic sur-
gery (67%), and laparotomy (66%). However, these studies 
were conducted with very small patient cohorts (n = 89 and 
75, respectively) and only 1-year follow-up periods.
In surveys, members of the Society of Gynecologic 
Oncology (SGO) reported positive attitudes toward and cur-
rent implementation of robotic surgery in practice [46, 47]. 
The data revealed the increased use of robotic surgery to 
treat uterine malignancies and ovarian cancer (especially in 
the early stages). In one survey, 66% of respondents wished 
to increase the use of robotic surgery in the future [46]. In the 
other survey, 97% of respondents reported the use of robotic 
surgery, especially for the treatment of cervical and endome-
trial cancers [47]. In agreement with the AGE respondents, 
the SGO respondents favored additional research on the use 
of robotic surgery to treat ovarian tumors [46]. The more 
widespread use of robotic surgery in the Anglo-American 
region than in Germany may be due, among other factors, to 
differences in the remuneration system. In 2019, for exam-
ple, a large portion of radical hysterectomies was performed 
robotically [37].
Limitations of the present study include the low response 
rate and the selection bias generated by surveying exclu-
sively (laparoscopy-favoring) AGE members. Future surveys 
on the use of robotic surgery for ovarian tumor treatment 
should be conducted with larger and more diverse groups. 
Another limiting factor was the lack of reliable data on surgi-
cal robot use in German gynecological hospitals, which pre-
vented, for example, determination of the ratio of respond-
ents using robotic surgery to the number of robots present in 
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their facilities. The collection of precise data on the quantity 
and distribution of surgical robots in Germany is crucial for 
subsequent surveys. A limitation of the present work is the 
imprecision of the question about the concerns regarding the 
oncologic safety of robotic surgery as, this question related 
to MIC in general and did not distinguish between robotic 
and laparoscopic surgery. Interpreting the results, we must 
consider the fact that the survey was carried out in 2015. 
Given the rapid progress in the surgical field, especially in 
terms of the use of MIS, a limitation of the present study 
could be the modified opinion of the AGE members regard-
ing the use of robotic surgery in 2020.
Conclusion
The present survey should give an impression of the current 
tendencies of German AGE members (albeit in a laparo-
scopic oriented group) and the current practice in German 
hospitals. Prospective randomized studies on the therapy 
of T1/2 ovarian tumors as well as borderline tumors of the 
ovary should be implemented according to the results of 
this survey.
Giving the current evidence, robotic surgery for the treat-
ment of ovarian malignancies should only be performed on 
selected patients within clinical studies.
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